Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LADIGAGA
2024-510741-33-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of dimethyl fumarate in age-related macular degeneration (AMD), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Rate of change in area of geographic atrophy at 12 months. Planned start Jun 2024; status: authorised.
02
Drugs
dimethyl fumarate
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2024-510741-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510741-33-00.